Original Article
Cetuximab for the Treatment of Colorectal Cancer
N Engl J Med 2007; 357:2040-2048November 15, 2007
- Abstract
Background
Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR.
Methods
From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival.
Results
In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001).
Conclusions
Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066.)
Media in This Article
Figure 1
Kaplan–Meier Curves for Overall Survival (Panel A) and Progression-free Survival (Panel B).Figure 2
Forest Plot Demonstrating Hazard Ratios for Death According to Planned Subgroup Analysis.Article Activity
- Article
Colorectal cancer has a worldwide annual incidence of 917,000 and is the second leading cause of cancer-related death in Western nations.1 The cytotoxic agents irinotecan, oxaliplatin, and the fluoropyrimidines, as well as bevacizumab, the antibody against vascular endothelial growth factor A, have increased the median survival of patients with advanced colorectal cancer,2-9 but in most patients the disease is incurable.
Recent advances have led to the development of agents that specifically inhibit tumor growth. Epidermal growth factor receptor (EGFR) is often up-regulated in colorectal cancer. Cetuximab, a chimeric IgG1 monoclonal antibody that binds to the extracellular domain of EGFR, blocks ligand-induced receptor signaling and modulates tumor-cell growth. Immune-mediated antitumor mechanisms, such as antibody-dependent cell-mediated cytotoxicity, may also contribute to the activity of cetuximab.10,11 Cetuximab has activity in colorectal cancer12 and can reverse drug resistance in patients with colorectal cancer when administered with irinotecan.13,14 However, to our knowledge, no trials have demonstrated an effect of cetuximab on survival or quality of life in patients with advanced colorectal cancer. We report a randomized trial that was conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG).
Methods
The study was designed by a protocol committee that included members of the NCIC CTG and the AGITG. The NCIC CTG collected, managed, and analyzed the data. Employees of Bristol-Myers Squibb and all the other authors reviewed the final manuscript and provided comments on it. NCIC CTG maintains full unrestricted rights to publication of the study data. Prepublication confidentiality of results was maintained by both the NCIC CTG and Bristol-Myers Squibb. The relevant institutional review boards approved the protocol, and all participants gave written informed consent.
Eligible patients had advanced colorectal cancer expressing EGFR that was detectable by immunohistochemical methods in a central reference laboratory. The patients either had been treated with a fluoropyrimidine (e.g., fluorouracil or capecitabine), irinotecan, and oxaliplatin with no response to treatment (as defined by unacceptable adverse events or progression of the tumor within 6 months of completion of treatment) or had contraindications to treatment with these drugs. The patients had disease that could be measured or otherwise evaluated; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; adequate bone marrow, kidney, and liver function; and no serious concurrent illness. Patients were ineligible if they had received any agent that targets the EGFR pathway (e.g., cetuximab, erlotinib, gefitinib, or panitumumab) or treatment with a murine monoclonal antibody. Previous bevacizumab therapy was permitted but not required.
Randomization
Eligible patients were stratified according to center and ECOG performance status (0 or 1 vs. 2) and randomly assigned between December 2003 and August 2005 at a 1:1 ratio to cetuximab plus best supportive care or best supportive care alone. Randomization was performed by the NCIC CTG central office with the use of a minimization method that dynamically balanced patients according to stratification factors.15 The database was maintained by the NCIC CTG.
Treatments
All patients received best supportive care, which was defined as those measures designed to provide palliation of symptoms and improve quality of life as much as possible. Because the patients had cancer that was refractory to all recommended chemotherapy, further chemotherapy or other antineoplastic therapy was not intended, although some patients did receive therapy after the completion of protocol procedures.
Cetuximab was given intravenously as an initial dose of 400 mg per square meter of body-surface area, administered over a period of 120 minutes, followed by a weekly maintenance infusion of 250 mg per square meter, administered over a period of 60 minutes. An antihistamine was given 30 to 60 minutes before each dose of cetuximab. Treatment was continued until death, in the absence of the occurrence of unacceptable adverse events, tumor progression, worsening symptoms of the cancer, or request by the patient, with or without the withdrawal of consent for continued follow-up.
Assessments
All patients were assessed every 4 weeks. Telephone monitoring was conducted until death for patients unable to attend the clinic. Chest radiographs and cross-sectional imaging were performed at baseline and every 8 weeks in both study groups until tumor progression occurred. Quality of life was assessed by the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire (QLQ-C30) at baseline and at 4, 8, 16, and 24 weeks after randomization.16,17
Statistical Analysis
The primary end point of this study was overall survival, defined as the time from randomization until death from any cause. It was estimated a priori that 445 deaths would provide a statistical power of 90% and a two-sided alpha of 5% to detect an absolute increase of 9.6% in the 1-year overall survival from the predicted 1-year overall survival of 14.1% in the group assigned to supportive care alone (hazard ratio, 0.74). The final analysis was conducted after at least 445 patients were known to have died; March 6, 2006, was established as the data cutoff date.
The secondary end points were progression-free survival, defined as the time from randomization until the first objective observation of disease progression or death from any cause; response rates, defined according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST); and quality of life, assessed by mean changes in scores of physical function and global health status at 8 and 16 weeks. The safety profile of cetuximab was assessed according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 2.0.
All patients who underwent randomization were included in the efficacy analyses on the basis of the group to which they were assigned. Safety analysis was conducted on an on-treatment basis, contrasting patients who had at least one dose of cetuximab (including those who crossed over) with patients assigned to supportive care alone, and omitting patients who withdrew consent before any intervention. Time-to-event variables were summarized with the use of Kaplan–Meier plots. Primary comparisons of the treatment groups were made with the use of the stratified log-rank test adjusted for ECOG performance status at randomization. Hazard ratios with 95% confidence intervals were calculated from stratified Cox regression models with treatment group as the single factor.18 Quality-of-life scores for physical function and global health status were standardized to range from 0 to 100, with higher scores indicating better quality of life.14 Deterioration in these quality-of-life scores was defined a priori as a decline of 10 points or more from baseline. Discrete variables were compared with the use of Fisher's exact test, and continuous and ordinal categorical variables with the use of the Wilcoxon test. An exploratory analysis of the effect of other potential prognostic factors specified a priori in the protocol was conducted by a multivariable Cox regression model stratified according to ECOG performance status at randomization. All P values were two-sided, and no adjustment was made for multiple comparisons. The final analysis was conducted by the NCIC CTG.
Results
We randomly assigned 572 patients to treatment: 287 to cetuximab plus best supportive care and 285 to best supportive care alone. Four patients assigned to the cetuximab group never received the drug, and five patients assigned to receive supportive care alone subsequently received cetuximab off protocol. Six patients assigned to supportive care alone immediately withdrew their consent. Four patients (two in each group) were ineligible because of elevated bilirubin levels, other cancer, refusal to complete a quality-of-life assessment at baseline, or death on the date of randomization. All were included in the analyses. The two groups were similar with respect to baseline characteristics (Table 1Table 1
Baseline Characteristics of the Patients.). The median duration of follow-up was 14.6 months.Treatment
The median duration of cetuximab treatment was 8.1 weeks (range, 1 to 60). Thirty-three patients (11.5%) had at least one dose reduction; rash, characteristically an acneiform papulopustular rash involving the face and trunk, was the most frequent reason (3.5%). One or more dose omissions occurred in 136 patients; intercurrent illness, rash, and patient request were the most common reasons. In 45 patients (15.7%), the infusion rate was decreased or infusion was interrupted at least once, most often because of a hypersensitivity reaction. The median dose intensity of cetuximab infusion after the initial dose was 247 mg per square meter per week; the relative dose intensity (the ratio of the dose administered to the planned dose) was 90% or higher in 75% of patients. At the time of data cutoff, 271 of the 283 patients had discontinued cetuximab treatment. Progressive disease and symptomatic progression were the principal reasons for cessation of treatment.
Efficacy
Figure 1AFigure 1
Kaplan–Meier Curves for Overall Survival (Panel A) and Progression-free Survival (Panel B). shows overall survival in the two groups. A total of 456 deaths (222 in the cetuximab group and 234 in the supportive-care group) had occurred by the date of analysis. All except 6 of these 456 patients died of colorectal cancer. The addition of cetuximab to supportive care resulted in longer overall survival than did supportive care alone (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005). The median survival was 6.1 months in the cetuximab group and 4.6 months in the supportive-care group. The proportions of patients surviving at 6 and 12 months were 50% and 21%, respectively, in the cetuximab group and 33% and 16%, respectively, in the supportive-care group. This difference remained statistically significant after adjustment for other protocol-specified potential prognostic factors with the use of a multivariable Cox regression model (hazard ratio, 0.79; 95% CI, 0.65 to 0.95; P=0.01). Factors other than treatment that were associated with survival in the multivariable analysis were sex; baseline levels of lactic dehydrogenase, alkaline phosphatase, and hemoglobin; and number of disease sites.In a planned subgroup analysis, no significant differences in the relative benefit of cetuximab were seen across subgroups defined on the basis of ECOG performance status at baseline, age, or sex (Figure 2Figure 2
Forest Plot Demonstrating Hazard Ratios for Death According to Planned Subgroup Analysis.). An unplanned landmark-type analysis that excluded all patients who died within 28 days after the start of the study demonstrated that the grade of rash in patients receiving cetuximab was strongly correlated with overall survival, with median survival of 2.6 months in patients with no rash, as compared with 4.8 months in patients with grade 1 rash and 8.4 months in patients with grade 2 rash (P<0.001) (Figure 3Figure 3
Overall Survival According to the Worst Grade of Rash in the Cetuximab Group.). The median time to the onset of a rash in patients who received cetuximab was 10 days; in 90% of patients with a rash, the rash developed within 29 days.Objective progression of the tumor was observed in 402 patients (224 in the cetuximab group and 178 in the supportive-care group), and 140 patients (49 in the cetuximab group and 91 in the supportive-care group) died without documented objective progression. Treatment with cetuximab resulted in a significant improvement in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001) (Figure 1B). This difference remained statistically significant after adjustment for other protocol-specified potential prognostic factors (hazard ratio, 0.71; 95% CI, 0.59 to 0.85; P<0.001). Similar relative benefits of cetuximab in terms of progression-free survival were seen in subgroups defined on the basis of ECOG performance status at baseline, age, and sex. The estimated proportions of patients who were alive without documented objective progression of disease at 3 and 6 months were 41% and 15%, respectively, in the cetuximab group and 24% and 3%, respectively, in the supportive-care group.
Twenty-three patients (8.0%) in the cetuximab group and none in the supportive-care group had partial responses (P<0.001). Stable disease was observed in 90 patients in the cetuximab group (31.4%) and 31 patients in the supportive-care group (10.9%, P<0.001).
Compliance with the quality-of-life questionnaire was 94% at baseline in both groups, 81% at 8 weeks and 67% at 16 weeks in the cetuximab group, and 62% at 8 weeks and 43% at 16 weeks in the supportive-care group. As compared with supportive care alone, cetuximab treatment was associated with less deterioration in physical function at 8 weeks (mean change score, –3.9 vs. –8.6; P<0.05 by the Wilcoxon test) and 16 weeks (mean change score, –5.9 vs. –12.5; P=0.03). Cetuximab treatment was also associated with less deterioration in global health status at 8 weeks (mean change score, –0.5 vs. –7.1; P=0.008) and 16 weeks (mean change score, –3.6 vs. –15.2; P<0.001).
Safety
Adverse events of interest or with an incidence of at least 5% at grade 3 or higher, according to the NCI-CTC, version 2.0, are summarized in Table 2Table 2
Adverse Events.. There were no statistically significant differences between the cetuximab group and the supportive-care group in the incidence of grade 3 or higher adverse events, with the exception of rash (11.8% for cetuximab vs. 0.4% for supportive care, P<0.001), infection without neutropenia (12.8% vs. 5.5%, P=0.003), confusion (5.6% vs. 2.2%, P=0.05), and pain defined as “other” according to the NCI-CTC (14.9% vs. 7.3%, P=0.005). Hematologic adverse events were uncommon, and there were no significant differences between the groups in grade 3 or higher (according to the NCI-CTC) serum chemical values or other laboratory measurements, with the exception of hypomagnesemia, which was more common in the cetuximab group than in the group receiving supportive care alone (5.8% vs. 0.0%, P<0.001). Grade 3 or 4 infusion reactions (hypersensitivity) occurred in 4.5% of patients assigned to cetuximab.As compared with patients in the supportive-care group, patients in the cetuximab group had a higher incidence of rash of any grade (88.6% vs. 16.1%, P<0.001), hypomagnesemia of any grade (53.3% vs. 15.1%, P<0.001), and infusion reactions of any grade (20.5% vs. 0.0%, P<0.001).
Fifty-nine patients died within 30 days after the last date of the cetuximab infusion. All died of colorectal cancer except one patient who had a pulmonary embolus. Eleven patients had adverse events leading to discontinuation of cetuximab, most frequently because of an infusion reaction.
Discussion
This study showed that cetuximab can improve overall survival in patients with colorectal cancer in whom other treatments have failed. Cetuximab alone — not in combination with other agents — improved survival. This trial was not blinded, which raises the possibility of bias in the assessment of progression-free survival but not overall survival. The hazard ratios for death (0.77) and disease progression or death (0.68) suggest minimal bias.
The interpretation of quality-of-life data is complicated by differences in compliance rates between the two groups; rapid disease progression in the group assigned to supportive care alone is likely to have resulted in a lower compliance rate. The tumor response rates were similar to rates reported in previous studies of cetuximab and other anti-EGFR antibodies.12,13 Our results suggest that stabilization of disease and response to the treatment contribute to the prolongation of survival but that tumor response alone may not be a useful surrogate outcome.
Initial studies of the treatment of colorectal cancer with cetuximab were performed in patients whose tumors had immunohistochemically detectable EGFR, but there is evidence that the intensity of staining of the tumor section for EGFR correlates poorly with the response to cetuximab. Moreover, responses have been reported in patients with tumors without immunohistochemically detectable EGFR.19,20 Although it is unknown whether the improvements in survival can be extrapolated to the patients with EGFR-negative tumors, immunohistochemically detectable EGFR is no longer considered a clinically useful biomarker.21
This study further validates the use of EGFR as a biologic target in colorectal cancer; however, not all EGFR inhibitors are equally efficacious against this disease. The EGFR tyrosine kinase inhibitors erlotinib and gefitinib have less activity against EGFR than do monoclonal antibodies.22,23 A study that compared the human anti-EGFR monoclonal antibody panitumumab with supportive care found a decrease in the time to progression of the disease but no improvement in overall survival with panitumumab.24
Cetuximab has the ability to reverse resistance to irinotecan.13 Studies in which cetuximab was combined with irinotecan in the treatment of colorectal cancer found improvements in response rates and progression-free survival but not in overall survival.13,25-27 The uncoupling of overall survival benefits from progression-free survival benefits in these combination studies is probably due in part to intentional or unintentional crossover, whereby patients assigned initially to a group without cetuximab eventually received cetuximab after progression. If the absolute survival benefit of cetuximab is similar whether it is given earlier or later in the course of treatment for advanced colorectal cancer, no survival difference will be seen in studies with substantial crossover. In contrast to the findings of these combination studies, only 7.0% of patients in our trial who were receiving supportive care alone subsequently received cetuximab, and only 27.5% of patients in the cetuximab group, versus 23.2% of patients in the supportive-care group, received any anticancer treatment after progression of the disease. The collective data suggest that cetuximab can benefit patients with advanced colorectal cancer, whether their disease is resistant or sensitive to chemotherapy.
Tumor progression had occurred in more than 50% of patients in both groups of our study by the time of the first computed tomographic scan, and the median progression-free survival did not differ between the groups (1.8 months in the supportive-care group vs. 1.9 months in the cetuximab group). However, the hazard ratio of 0.68 for disease progression or death is reflected in a clear separation of the curves after the median.
The disease was stable or responded to therapy in only 39.4% of the patients in the cetuximab group, a result indicating a need for predictive biomarkers to identify patients who could benefit from such treatment. Rash related to EGFR inhibition, which is due to alteration of the mediation of epidermal basal keratinocytes by EGFR, is one such potential biomarker. Analysis of the incidence of the rash suggests that it may be a predictive marker, but this point has not been validated.
Supported by the National Cancer Institute of Canada, ImClone Systems, and Bristol-Myers Squibb.
Drs. O'Callaghan and Tu are employees of the National Cancer Institute of Canada Clinical Trials Group, which has received grant support from Bristol-Myers Squibb and Amgen Canada. Drs. Simes and Zalcberg report receiving research grants from Bristol-Myers Squibb; and Dr. Zalcberg, consulting fees from Amgen. Dr. Langer owns equity in and is an employee of Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.
Drs. Jonker and O'Callaghan contributed equally to this article.
Source Information
From Ottawa Hospital Research Institute, University of Ottawa, Ottawa (D.J.J.); National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON (C.J.O., D.T.); Flinders Medical Centre, Adelaide, Australia (C.S.K.); Peter MacCallum Cancer Centre and Department of Medicine, University of Melbourne, Melbourne, Australia (J.R.Z.); Cross Cancer Institute, Edmonton, AB, Canada (H.-J.A.); Toronto–Sunnybrook Regional Cancer Centre, Toronto (S.R.B.); St. Boniface General Hospital, Winnipeg, MB, Canada (M.K.); Queen Elizabeth Hospital, Adelaide, Australia (T.P.); National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (R.J.S.); Austin Health, Melbourne, Australia (N.C.T.); Sir Charles Gairdner Hospital, Perth, Australia (G.H.); Lakeridge Health, Oshawa, ON, Canada (R.W.); Bristol-Myers Squibb, Wallingford, CT (C.L.); and Princess Margaret Hospital, Toronto (M.J.M.).
Address reprint requests to Dr. Jonker at the Ottawa Hospital Regional Cancer Centre, University of Ottawa, 501 Smyth Rd., Box 912, Ottawa, ON K1H 8L6, Canada, or at djonker@ottawahospital.on.ca.
Other participants in the CO.17 Trial from the National Cancer Institute of Canada Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group are listed in the Appendix.
Appendix
In addition to the authors, the following committee members, site investigators, data managers, and key trial staff participated in the CO.17 study from the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). NCIC CTG investigators in Canada: Dr. H. Bliss Murphy Cancer Centre, St. John's, NB — J. Siddiqui; QEII Health Sciences Center, Halifax, NS — B. Colwell; Atlantic Health Sciences Corporation, St. John's, NB — M. Burnell; Moncton Hospital, Moncton, NB — S. Rubin; Hôpital du Sacré-Coeur de Montréal, Montreal — R. Whittom; Centre Hospitalier de l'Université de Montréal–Hôpital Notre-Dame, Montreal — D. Charpentier; Hôpital Charles LeMoyne, Greenfield Park, QC — B. Samson; Cancer Centre of Southeastern Ontario, Kingston — A. Tomiak; Quinte Healthcare Corporation, Belleville, ON — R. Levesque; Niagara Health System, Ontario — B. Findlay; Toronto East General Hospital, Toronto — J. Meharchand; St. Joseph's Health Centre, Toronto — J. Blondal; Mount Sinai Hospital, Toronto — R. Burkes; St. Michael's Hospital, Toronto — R. Haq; Grand River Regional Cancer Centre, Kitchener, ON — G. Knight; London Regional Cancer Program, Ontario — I. Kerr; Windsor Regional Cancer Centre, Ontario — J. Mathews; Thunder Bay Regional Health Science Centre, North Bay, ON — D. Dueck; Allan Blair Cancer Centre, Regina, SK — H. Chalchal; Saskatoon Cancer Centre, Saskatoon, SK — S. Yadav; Cross Cancer Institute, Edmonton, AB — S. Koski; BC Cancer Agency–Vancouver Cancer Centre, Vancouver, BC — H. Kennecke; BC Cancer Agency–Cancer Centre for the Southern Interior, Kelowna, BC — M. Taylor; BC Cancer Agency–Vancouver Island Cancer Centre, Victoria, BC — H. Anderson; BC Cancer Agency–Fraser Valley Cancer Centre, Surrey, BC — U. Lee. NCIC CTG central office staff, Kingston, ON: S. Robitaille, N. Magoski, S. Hunt, A. Lewis, D. Nomikos, J. Ottaway, A. Hung, A. Sargeant, V. Classen, J. Baran, L. Pho, A. Garrah, L. Zhu. Australasian Gastro-Intestinal Trials Group (AGITG) investigators in Australia: Newcastle Mater Misericordiae Hospital, New South Wales — S. Ackland; Port Macquarie Base Hospital, New South Wales — S. Begbie; St. Vincent's Hospital, Victoria — I. Burns; Launceston General Hospital, Tasmania — I. Byard; Fremantle Hospital, Western Australia — P. Claringbold; Royal Melbourne Hospital, Victoria — P. Gibbs; Prince of Wales Hospital, New South Wales — D. Goldstein; Peter MacCallum Cancer Institute, Victoria — M. Jefford; St. George Hospital, New South Wales — M. Links; Royal Hobart Hospital, Tasmania — R. Lowenthal; Brisbane Adult Mater, Queensland — P. Mainwaring; Royal North Shore Hospital, New South Wales — N. Pavlakis; St. John of God Subiaco, Western Australia — D. Ransom; Nepean Hospital, New South Wales — J. Shannon; Cabrini Hospital, Victoria, and Alfred Hospital, Victoria — J. Shapiro; Monash Medical Centre, Victoria — A. Strickland; Royal Perth Hospital, Western Australia — J. Trotter; Border Medical Oncology, Victoria — C. Underhill; Royal Brisbane Hospital, Queensland — D. Wyld; Canberra Hospital, Australian Capital Territory — D. Yip. AGITG investigators in New Zealand: Palmerston North Hospital, Palmerston North — R. Isaacs; Christchurch Hospital, Christchurch — M. Jeffrey. AGITG investigator in Singapore: National Cancer Centre Singapore — K.F. Foo. Australian National Health and Medical Research Council (NHMRC) Clinical Trials Centre (AGITG Coordinating Centre) staff: B. Cakir, A. Pearce, C. Aiken, J. Simard-Lebrun, J. Shoulder, F. Howard. Bristol-Myers Squibb: J. Dechamplain, N. Gustafson.
- References
References
1
Mathers C, Boschi-Pinto C. Global burden of cancer in the year 2000: version 1 estimates. Geneva: World Health Organization, 2006.
2
Cassidy J ,Twelves C ,Van Cutsem E , et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575
CrossRef | Web of Science | Medline3
Cunningham D ,Pyrhonen S ,James RD , et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418
CrossRef | Web of Science | Medline4
Rougier P ,Van Cutsem E ,Bajetta E , et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412[Erratum, Lancet 1998;352:1634.]
CrossRef | Web of Science | Medline5
Saltz LB ,Cox JV ,Blanke C , et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914
Full Text | Web of Science | Medline6
Douillard JY ,Cunningham D ,Roth AD , et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047[Erratum, Lancet 2000;355:1372.]
CrossRef | Web of Science | Medline7
Goldberg RM ,Sargent DJ ,Morton RF , et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
CrossRef | Web of Science | Medline8
Grothey A ,Sargent D ,Goldberg RM ,Schmoll HJ . Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214
CrossRef | Web of Science | Medline9
Hurwitz H ,Fehrenbacher L ,Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
Full Text | Web of Science | Medline10
Mellstedt H . Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003;39:Suppl C:1-16
Web of Science | Medline11
Mendelsohn J ,Baselga J . The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565
CrossRef | Web of Science | Medline12
Saltz LB ,Meropol NJ ,Loehrer PJ ,Needle MN ,Kopit J ,Mayer RJ . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208
CrossRef | Web of Science | Medline13
Cunningham D ,Humblet Y ,Siena S , et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345
Full Text | Web of Science | Medline14
Saltz LB ,Lenz H-J ,Kindler HL , et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557-4561
CrossRef | Web of Science | Medline15
Tu D. Minimization procedure. In: Chow S-C, ed. Encyclopedia of biopharmaceutical statistics. Rev. 2nd ed. New York: Marcel Dekker, 2003:614-8.
16
Aaronson NK ,Ahmedzai S ,Bergman B , et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376
CrossRef | Web of Science | Medline17
Feeny D ,Furlong W ,Boyle M ,Torrance GW . Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 1995;7:490-502
CrossRef | Web of Science | Medline18
Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer, 1997.
19
Chung KY ,Shia J ,Kemeny NE , et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810
CrossRef | Web of Science | Medline20
Hebbar M ,Wacrenier A ,Desauw C , et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006;17:855-857
CrossRef | Web of Science | Medline21
NCCN clinical practice guidelines in oncology: colon cancer: V.2.2007. COL-C (2 of 5). Jenkintown, PA: National Comprehensive Cancer Network, 2007. (Accessed October 19, 2007, at http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.)
22
Townsley CA ,Major P ,Siu LL , et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006;94:1136-1143
CrossRef | Web of Science | Medline23
Rothenberg ML ,LaFleur B ,Levy DE , et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-9274
CrossRef | Web of Science | Medline24
Van Cutsem E ,Peeters M ,Siena S , et al. Open-label phase III trial of panitumumab plus best supportive care with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664
CrossRef | Web of Science | Medline25
Sobrero A, Fehrenbacher L, Rivera F, et al. Randomized Phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial. Presented at the Annual Meeting 2007 of the American Association for Cancer Research, Los Angeles, April 14–18, 2007. abstract. (Accessed October 19, 2007, at http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={767B9C4F-1482-4E0A-855C-9B223D802DE3}&MKey={E3F4019C-0A43-4514-8F66-B86DC90CD935}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}&SKey={FA30AEE6-5964-4270-8253-C16F6E2F75DA}.)
26
Eng C ,Maurel J ,Scheithauer W , et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. J Clin Oncol 2007;25:Suppl:18s-18s27
Van Cutsem E ,Nowacki M ,Lang I , et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mcolorectal cancer): the CRYSTAL trial. J Clin Oncol 2007;25:Suppl:18s-18s
- Citing Articles (316)
Citing Articles
1
Kathryn Vanderlaag, Wei Wang, Laurence Fayadat-Dilman, Janet Wagner, Laura Bald, Jeff Grein, Mary J. Janatpour. (2012) Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer. International Journal of Cancer 130:6, 1251-1263
CrossRef2
Timothy A. Yap, Paul Workman. (2012) Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology 52:1, 549-573
CrossRef3
N Steele, A Anthony, M Saunders, B Esmarck, E Ehrnrooth, P E G Kristjansen, A Nihlén, L T Hansen, J Cassidy. (2012) A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. British Journal of Cancer
CrossRef4
Alberto Bardelli, Pasi A Jänne. (2012) The road to resistance: EGFR mutation and cetuximab. Nature Medicine 18:2, 199-200
CrossRef5
Nagahiro Saijo. (2012) Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treatment Reviews 38:1, 63-67
CrossRef6
Sascha Tierling, Christine Sers, Annika Lehmann, Jörn Walter. (2012) A fast, cost-efficient and sensitive approach for KRAS mutation detection using multiplexed primer extension with IP/RP-HPLC separation. International Journal of Cancer 130:3, 567-574
CrossRef7
Lida Wang, Xuemei Chen, Wei Li, Zhixin Sheng. (2012) Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer. Anti-Cancer Drugs 23:2, 155-160
CrossRef8
Shishir K. Maithel, Mithat Gönen, Hiromichi Ito, Ronald P. DeMatteo, Peter J. Allen, Yuman Fong, Leslie H. Blumgart, William R. Jarnagin, Michael I. D'Angelica. (2012) Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery 151:2, 162-170
CrossRef9
S Yousuf Zafar, David C Currow, Nathan Cherny, Florian Strasser, Robin Fowler, Amy P Abernethy. (2012) Consensus-based standards for best supportive care in clinical trials in advanced cancer. The Lancet Oncology 13:2, e77-e82
CrossRef10
Catherine A Del Vecchio, Gordon Li, Albert J Wong. (2012) Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Review of Vaccines 11:2, 133-144
CrossRef11
Bengt Glimelius, Nina Cavalli-Björkman. (2012) Metastatic colorectal cancer: current treatment and future options for improved survival. Scandinavian Journal of Gastroenterology1-19
CrossRef12
P. Blinman, M. King, R. Norman, R. Viney, M. R. Stockler. (2012) Preferences for cancer treatments: an overview of methods and applications in oncology. Annals of Oncology
CrossRef13
David Páez, Melissa J. Labonte, Heinz-Josef Lenz. (2012) Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). Gastroenterology Clinics of North America
CrossRef14
Jaw-Yuan Wang, Ben-Kuen Chen, Yu-Shiuan Wang, Yao-Ting Tsai, Wei-Chiao Chen, Wen-Chang Chang, Ming-Feng Hou, Yang-Chang Wu, Wei-Chiao Chang. (2012) Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cellular Signalling 24:1, 162-169
CrossRef15
Simon Laban, Chia Jung Wang, Adrian Münscher, Silke Tribius, Philippe Schafhausen, Rainald Knecht, David W. Eisele. (2012) Molecular targeting agents in the context of primary chemoradiation strategies. Head & Neckn/a-n/a
CrossRef16
Arjun Sood, Danielle McClain, Radhashree Maitra, Atrayee Basu-Mallick, Raviraja Seetharam, Andreas Kaubisch, Lakshmi Rajdev, John M. Mariadason, Kathryn Tanaka, Sanjay Goel. (2012) PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer
CrossRef17
Carlos Rodríguez de Lope, Silvia Tremosini, Alejandro Forner, María Reig, Jordi Bruix. (2012) Management of HCC. Journal of Hepatology 56, S75-S87
CrossRef18
Dorothy M. K. Keefe, Emma H. Bateman. (2011) Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology
CrossRef19
Chakkarin Burudpakdee, Zhongyun Zhao, Julie Munakata, Sue Gao, Karen Trochlil, Beth Barber. (2011) Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. Journal of Medical Economics1-7
CrossRef20
Hannes P. Neeff, Oliver Drognitz, Andrea Klock, Gerald Illerhaus, Oliver G. Opitz, Ulrich T. Hopt, Frank Makowiec. (2011) Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. International Journal of Colorectal Disease
CrossRef21
Steven R. Alberts, Graeme J. Poston. (2011) Treatment Advances in Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer 10:4, 258-265
CrossRef22
Andreia Costa, Sabine Tejpar, Hans Prenen, Eric Van Cutsem. (2011) Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Targeted Oncology 6:4, 227-233
CrossRef23
Alessandro Inno, Mariantonietta Di Salvatore, Tonia Cenci, Maurizio Martini, Armando Orlandi, Antonia Strippoli, Anna Maria Ferrara, Cinzia Bagalà, Alessandra Cassano, Luigi Maria Larocca, Carlo Barone. (2011) Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?. Clinical Colorectal Cancer 10:4, 325-332
CrossRef24
Sumithra J Mandrekar, Daniel J Sargent. (2011) Design of clinical trials for biomarker research in oncology. Clinical Investigation 1:12, 1627-1636
CrossRef25
Hao Zhuang, Zhen-yi Xue, Lu Wang, Xiao-yan Li, Ning Zhang, Rong-xin Zhang. (2011) Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer. Clinical Oncology and Cancer Research 8:4, 207-214
CrossRef26
Kohei Shitara, Takashi Ura, Keitaro Matsuo, Daisuke Takahari, Tomoya Yokota, Satoshi Yuki, Motoki Yoshida, Setsuo Utsunomiya, Yozo Sato, Hidekazu Yamaura, Mina Kato, Yoshitaka Inaba, Masahiro Tajika, Hiroki Kawai, Kentaro Yamazaki, Yoshito Komatsu, Kei Muro. (2011) Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. European Journal of Cancer 47:18, 2673-2680
CrossRef27
Vikram K. Jain, Eliza A. Hawkes, David Cunningham. (2011) Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 10:4, 245-257
CrossRef28
Alexander Stein, Sonja Hiemer, Hans-Joachim Schmoll. (2011) Adjuvant Therapy for Early Colon Cancer. Drugs 71:17, 2257-2275
CrossRef29
B Melichar, E Casado, J Bridgewater, J Bennouna, M Campone, P Vitek, J-P Delord, J Cerman, R Salazar, J Dvorak, C Sguotti, P Urban, K Viraswami-Appanna, E Tan, J Tabernero. (2011) Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. British Journal of Cancer 105:11, 1646-1653
CrossRef30
A. Kay, J. Higgins, A. G. Day, R. M. Meyer, C. M. Booth. (2011) Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Annals of Oncology
CrossRef31
Gaetana Di Fede, Giuseppe Bronte, Sergio Rizzo, Christian Rolfo Cervetto, Gianfranco Cocorullo, Gaspare Gulotta, Viviana Bazan, Antonio Russo. (2011) Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy 11:11, 1433-1445
CrossRef32
Philipp Erben, Philipp Ströbel, Karoline Horisberger, Juliana Popa, Beatrice Bohn, Benjamin Hanfstein, Georg Kähler, Peter Kienle, Stefan Post, Frederik Wenz, Andreas Hochhaus, Ralf-Dieter Hofheinz. (2011) KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics 81:4, 1032-1038
CrossRef33
Muhammad A. Khattak, Amanda R. Townsend, Carol Beeke, Christos S. Karapetis, Colin Luke, Rob Padbury, Guy Maddern, David Roder, Timothy J. Price. (2011) Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer
CrossRef34
J.M. Baas, L.L. Krens, H.-J. Guchelaar, J. Ouwerkerk, F.A de Jong, A.P.M. Lavrijsen, H. Gelderblom. (2011) Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treatment Reviews
CrossRef35
Y. Balagula, S. Wu, X. Su, M. E. Lacouture. (2011) The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Annals of Oncology 22:11, 2366-2374
CrossRef36
Emmanuelle Norguet, Laetitia Dahan, Jean Gaudart, Mohamed Gasmi, L’houcine Ouafik, Jean-François Seitz. (2011) Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?. Digestive and Liver Disease 43:11, 917-919
CrossRef37
Jen-Kou Lin, An-Jen Lin, Chun-Chi Lin, Yuan-Tzu Lan, Shung-Haur Yang, Anna Fen-Yau Li, Shih-Ching Chang. (2011) The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. Journal of Surgical Oncology 104:6, 661-666
CrossRef38
M. G. Fakih, A. Groman, J. McMahon, G. Wilding, J. R. Muindi. (2011) A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemotherapy and Pharmacology
CrossRef39
, Toshiaki Watanabe, Michio Itabashi, Yasuhiro Shimada, Shinji Tanaka, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Ichinosuke Hyodo, Masahiro Igarashi, Hideyuki Ishida, Megumi Ishiguro, Yukihide Kanemitsu, Norihiro Kokudo, Kei Muro, Atsushi Ochiai, Masahiko Oguchi, Yasuo Ohkura, Yutaka Saito, Yoshiharu Sakai, Hideki Ueno, Takayuki Yoshino, Takahiro Fujimori, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Keiichi Takahashi, Hiroya Takiuchi, Osamu Tsuruta, Toshiharu Yamaguchi, Masahiro Yoshida, Naohiko Yamaguchi, Kenjiro Kotake, Kenichi Sugihara. (2011) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. International Journal of Clinical Oncology
CrossRef40
Dominik P. Modest, Sebastian Stintzing, Ruediger P. Laubender, Jens Neumann, Andreas Jung, Clemens Giessen, Michael Haas, Philipp Aubele, Christoph Schulz, Stefan Boeck, Hans-Joachim Stemmler, Thomas Kirchner, Volker Heinemann. (2011) Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anti-Cancer Drugs 22:9, 913-918
CrossRef41
Hongbo Yang, Andrew P. Yu, Eric Q. Wu, Yeun Mi Yim, Elaine Yu. (2011) Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. Journal of Medical Economics 14:5, 542-552
CrossRef42
Jean Boucher, Linnea Olson, Bilal Piperdi. (2011) Preemptive Management of Dermatologic Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors. Clinical Journal of Oncology Nursing 15:5, 501-508
CrossRef43
José María Viéitez, Manuel Valladares, Ignacio Peláez, Luis Sande González, Jesús García-Foncillas, José Luis García-López, Carlos García-Girón, Margarita Reboredo, Humberto Bovio, Angel Jiménez Lacave. (2011) A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). Investigational New Drugs 29:5, 1038-1044
CrossRef44
Paul HS Shaw, Richard A Adams. (2011) Where now for anti-EGF receptor therapies in colorectal cancer?. Expert Review of Anticancer Therapy 11:10, 1543-1553
CrossRef45
D.I. Pryor, E. Burmeister, B.H. Burmeister, M.G. Poulsen, S.V. Porceddu. (2011) Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. Oral Oncology 47:10, 984-987
CrossRef46
A C Mita, K Papadopoulos, M J A de Jonge, G Schwartz, J Verweij, M M Mita, A Ricart, Q S-C Chu, A W Tolcher, L Wood, S McCarthy, M Hamilton, K Iwata, B Wacker, K Witt, E K Rowinsky. (2011) Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British Journal of Cancer 105:7, 938-944
CrossRef47
Finn Ole Larsen, Mogens Karsbøl Boisen, Annelene L. Fromm, Benny Vittrup Jensen. (2011) Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. Acta Oncologica1-3
CrossRef48
K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, D. Ercan, A. Rogers, M. Roncalli, M. Takeda, Y. Fujisaka, J. Philips, T. Shimizu, O. Maenishi, Y. Cho, J. Sun, A. Destro, K. Taira, K. Takeda, T. Okabe, J. Swanson, H. Itoh, M. Takada, E. Lifshits, K. Okuno, J. A. Engelman, R. A. Shivdasani, K. Nishio, M. Fukuoka, M. Varella-Garcia, K. Nakagawa, P. A. Janne. (2011) Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine 3:99, 99ra86-99ra86
CrossRef49
Athanassios Argiris, Trevor M. Feinstein, Lin Wang, Tianbing Yang, Shruti Agrawal, Leonard J. Appleman, Ronald G. Stoller, Jennifer R. Grandis, Ann Marie Egloff. (2011) Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Investigational New Drugs
CrossRef50
Tetsuya Homma, Masatsugu Kurokawa, Yoshitaka Yamamoto, Satoshi Matsukura, Koushi Ieki, Shintaro Suzuki, Miho Odaka, Shin Watanabe, Munehiro Yamaguchi, Mitsuru Adachi. (2011) Oxaliplatin-induced lung injury with allergic reaction. Chinese Journal of Cancer Research 23:3, 232-235
CrossRef51
Santiago Aparo, Sanjay Goel. (2011) Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Critical Reviews in Oncology/Hematology
CrossRef52
Vinochani Pillay, Hui K. Gan, Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, 518-529
CrossRef53
Aimery de Gramont. (2011) Re-challenge and the concept of lines of therapy in metastatic colorectal cancer. European Journal of Cancer 47, S76-S84
CrossRef54
Marc Peeters, Timothy Price. (2011) Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice. Cancer Treatment Reviews
CrossRef55
Carol Beadling, Michael C. Heinrich, Andrea Warrick, Erin M. Forbes, Dylan Nelson, Emily Justusson, Judith Levine, Tanaya L. Neff, Janice Patterson, Ajia Presnell, Arin McKinley, Laura J. Winter, Christie Dewey, Amy Harlow, Oscar Barney, Brian J. Druker, Kathryn G. Schuff, Christopher L. Corless. (2011) Multiplex Mutation Screening by Mass Spectrometry. The Journal of Molecular Diagnostics 13:5, 504-513
CrossRef56
Fausto Petrelli, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Sandro Barni. (2011) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opinion on Drug Safety1-11
CrossRef57
Ayako Mizota, Kohei Shitara, Chihiro Kondo, Motoo Nomura, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Yoshitaka Inaba, Hidekazu Yamaura, Yozo Sato, Mina Kato, Kei Muro. (2011) Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer. International Journal of Clinical Oncology 16:4, 416-420
CrossRef58
David J. Gallagher, Hikmat Al-Ahmadie, Irina Ostrovnaya, Scott R. Gerst, Ashley Regazzi, Ilana Garcia-Grossman, Jamie Riches, Sivaraman K. Gounder, Anne-Marie Flaherty, Alisa Trout, Matthew I. Milowsky, Dean F. Bajorin. (2011) Sunitinib in Urothelial Cancer: Clinical, Pharmacokinetic, and Immunohistochemical Study of Predictors of Response. European Urology 60:2, 344-349
CrossRef59
Cheryl Ho, Randeep Sangha, Laurel Beckett, Michael Tanaka, Derick H. Lau, Daniel B. Eisen, Rachel A. Burich, Paul Luciw, Imran Khan, Philip C. Mack, David R. Gandara, Angela M. Davies. (2011) Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study. Investigational New Drugs 29:4, 680-687
CrossRef60
M. Koopman. (2011) Nieuwe ontwikkelingen bij de behandeling van coloncarcinoom. Huisarts en wetenschap 54:8, 450-454
CrossRef61
Janine M. Davies, Richard M. Goldberg. (2011) Treatment of Metastatic Colorectal Cancer. Seminars in Oncology 38:4, 552-560
CrossRef62
Isabelle Ray-Coquard, Axel Le Cesne. (2011) A role for maintenance therapy in managing sarcoma. Cancer Treatment Reviews
CrossRef63
Kohei Shitara, Tomoya Yokota, Daisuke Takahari, Takashi Shibata, Takashi Ura, Setsuo Utsunomiya, Yoshitaka Inaba, Hidekazu Yamaura, Yozo Sato, Mina Najima, Hiroki Kawai, Masahiro Tajika, Akira Sawaki, Yasushi Yatabe, Kei Muro. (2011) Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS. Investigational New Drugs 29:4, 688-693
CrossRef64
Benedito A. Carneiro, Ramesh K. Ramanathan, Marwan G. Fakih, Smitha S. Krishnamurthi, Barry C. Lembersky, Ronald G. Stoller, Stewart L. Lancaster, Richard A. Pinkerton, Theodore L. Crandall, Amy R. Schmotzer, Douglas M. Potter, Nathan Bahary. (2011) Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer. Clinical Colorectal Cancer
CrossRef65
Linlin Zhang, Li Ma, Qinghua Zhou. (2011) Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis. International Journal of Colorectal Disease 26:8, 1025-1033
CrossRef66
Ricarda Seidensticker, Timm Denecke, Patrick Kraus, Max Seidensticker, Konrad Mohnike, Jörg Fahlke, Erika Kettner, Bert Hildebrandt, Oliver Dudeck, Maciej Pech, Holger Amthauer, Jens Ricke. (2011) Matched-Pair Comparison of Radioembolization Plus Best Supportive Care Versus Best Supportive Care Alone for Chemotherapy Refractory Liver-Dominant Colorectal Metastases. CardioVascular and Interventional Radiology
CrossRef67
H. K. Chew, G. Somlo, P. C. Mack, B. Gitlitz, R. Gandour-Edwards, S. Christensen, H. Linden, L. J. Solis, X. Yang, A. M. Davies. (2011) Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Annals of Oncology
CrossRef68
S Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, M Stauch, H G Hass, H Dietzfelbinger, D Oruzio, S Klein, K Zellmann, T Decker, M Schulze, W Abenhardt, G Puchtler, H Kappauf, J Mittermüller, C Haberl, C Giessen, N Moosmann, V Heinemann. (2011) Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. British Journal of Cancer 105:2, 206-211
CrossRef69
Christopher R Garrett, Cathy Eng. (2011) Cetuximab in the treatment of patients with colorectal cancer. Expert Opinion on Biological Therapy 11:7, 937-949
CrossRef70
Eliza A. Hawkes, David Cunningham, Diana Tait, Gina Brown, Ian Chau. (2011) Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. Seminars in Radiation Oncology 21:3, 196-202
CrossRef71
Soichiro Ishihara, Toshiaki Watanabe, Takuya Akahane, Ryu Shimada, Atsushi Horiuchi, Hajima Shibuya, Tamuro Hayama, Hideki Yamada, Keijiro Nozawa, Hiroshi Igaki, Keiji Matsuda. (2011) Prognostic significance of adverse events associated with preoperative radiotherapy for rectal cancer. International Journal of Colorectal Disease 26:7, 911-917
CrossRef72
C R Garrett, L L Siu, A El-Khoueiry, J Buter, C M Rocha-Lima, J Marshall, P LoRusso, P Major, J Chemidlin, O Mokliatchouk, L Velasquez, W Hayes, D Feltquate, S Syed, S Ford, G Kollia, S Galbraith, D S A Nuyten. (2011) Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. British Journal of Cancer 105:1, 44-52
CrossRef73
Myoung Joo Kang, Yong Sang Hong, Kyu-pyo Kim, Sun Young Kim, Ji Yeon Baek, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Mi-Jung Kim, Hee Jin Chang, Yoon-Koo Kang, Tae Won Kim. (2011) Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Investigational New Drugs
CrossRef74
Alexandre Ho-Pun-Cheung, Eric Assenat, Caroline Bascoul-Mollevi, Frédéric Bibeau, Florence Boissière-Michot, Dominic Cellier, David Azria, Philippe Rouanet, Pierre Senesse, Marc Ychou, Evelyne Lopez-Crapez. (2011) EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. International Journal of Cancer 128:12, 2938-2946
CrossRef75
Marta Herreros-Villanueva, Gaurav Aggarwal. (2011) KRAS assay selection: sensitivity and accuracy in clinical application. Molecular Biology Reports
CrossRef76
J. A. Chan, L. S. Blaszkowsky, P. C. Enzinger, D. P. Ryan, T. A. Abrams, A. X. Zhu, J. S. Temel, D. Schrag, P. Bhargava, J. A. Meyerhardt, B. M. Wolpin, P. Fidias, H. Zheng, S. Florio, E. Regan, C. S. Fuchs. (2011) A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Annals of Oncology 22:6, 1367-1373
CrossRef77
Barbara-Ann Adelstein, Timothy A. Dobbins, Carole A. Harris, Ian C. Marschner, Robyn L. Ward. (2011) A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. European Journal of Cancer 47:9, 1343-1354
CrossRef78
C. Morales-Gutiérrez, A. Abad-Barahona, E. Moreno-González, R. Enríquez de Salamanca, I. Vegh. (2011) Tumour VEGF/Non Tumour VEGF protein expression ratio as a biomarker for survival in colorectal cancer patients. European Journal of Surgical Oncology (EJSO) 37:6, 526-531
CrossRef79
Lorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi, Giacomo Allegrini, Fotios Loupakis, Enrico Vasile, Samanta Cupini, Irene Stasi, Lisa Salvatore, Chiara Cremolini, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Francesco Graziano, Annamaria Ruzzo, Emanuele Canestrari, Mauro Magnani, Alfredo Falcone. (2011) Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Critical Reviews in Oncology/Hematology 78:3, 243-251
CrossRef80
S. Robinson, D.M. Manas, I. Pedley, D. Mann, S.A. White. (2011) Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surgical Oncology 20:2, 57-72
CrossRef81
Diocésio Pinto de Andrade, João Paulo Lima, Alan Duarte Lima, André Deeke Sasse, Lucas Vieira dos Santos. (2011) Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics. Anti-Cancer Drugs 22, S15-S17
CrossRef82
Yoshinari Asaoka, Tsuneo Ikenoue, Kazuhiko Koike. (2011) New targeted therapies for gastric cancer. Expert Opinion on Investigational Drugs 20:5, 595-604
CrossRef83
Finn Ole Larsen, Per Pfeiffer, Dorte Nielsen, Kristin Skougaard, Camilla Qvortrup, Kirsten Vistisen, Anne-Lene Fromm, Trine L. Jørgensen, Jon K. Bjerregaard, Estrid Hoegdall, Benny V. Jensen. (2011) Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncologica 50:4, 574-577
CrossRef84
Hui Chen, Joel A. Lefferts, Mary C. Schwab, Arief A. Suriawinata, Gregory J. Tsongalis. (2011) Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation. Cancer Genetics 204:5, 245-251
CrossRef85
Augusto Villanueva, Josep M. Llovet. (2011) Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology 140:5, 1410-1426
CrossRef86
Chul Kim, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Ho Young Lim, Hye Jin Kang, Young Suk Park, Baek-Yeol Ryoo, Yoon-Koo Kang. (2011) A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Investigational New Drugs 29:2, 366-373
CrossRef87
S. L. McDonald, A. R. Silver. (2011) On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling. Colorectal Disease 13:4, 360-369
CrossRef88
Ian D DAVIS. (2011) Update on monoclonal antibodies for the treatment of cancer. Asia-Pacific Journal of Clinical Oncology 7, 20-25
CrossRef89
Timothy M. Clay, Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, H. Kim Lyerly. (2011) Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunologic Research 49:1-3, 235-247
CrossRef90
Daniel V.T. Catenacci, Mark Kozloff, Hedy L. Kindler, Blase Polite. (2011) Personalized Colon Cancer Care in 2010. Seminars in Oncology 38:2, 284-308
CrossRef91
Shouji Shimoyama. (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemotherapy and Pharmacology 67:4, 729-739
CrossRef92
M. Joerger, K. Matter-Walstra, M. Fruh, U. Kuhnel, T. Szucs, B. Pestalozzi, M. Schwenkglenks. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of Oncology 22:3, 567-574
CrossRef93
V. E. P. P. Lemmens, N. Haan, H. J. T. Rutten, H. Martijn, O. J. L. Loosveld, R. M. H. Roumen, G. J. M. Creemers. (2011) Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992–2008. Clinical & Experimental Metastasis 28:3, 283-290
CrossRef94
Christopher T Harbison, Christine E Horak, Shirin Khambata-Ford. (2011) The cetuximab experience: developing predictive biomarkers in oncology. Personalized Medicine 8:2, 149-159
CrossRef95
Seung T KIM, Yoon J CHOI, Kyong H PARK, Sang C OH, Jae H SEO, Sang W SHIN, Jun S KIM, Yeul H KIM. (2011) Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology 7:1, 82-87
CrossRef96
Francis Lévi, Abdoulaye Karaboué, Lee Gorden, Pasquale Fabio Innominato, Raphael Saffroy, Sylvie Giacchetti, Dominique Hauteville, Catherine Guettier, René Adam, Mohamed Bouchahda. (2011) Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemotherapy and Pharmacology 67:2, 339-348
CrossRef97
Dawn Odom, Beth Barber, Lee Bennett, Marc Peeters, Zhongyun Zhao, James Kaye, Michael Wolf, Jeffrey Wiezorek. (2011) Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. International Journal of Colorectal Disease 26:2, 173-181
CrossRef98
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef99
Rafal Wierzbicki, Derek J. Jonker, Malcolm J. Moore, Scott R. Berry, Patrick J. Loehrer, Hagop Youssoufian, Eric K. Rowinsky. (2011) A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Investigational New Drugs 29:1, 167-174
CrossRef100
A. Ocana, I. F. Tannock. (2011) When Are "Positive" Clinical Trials in Oncology Truly Positive?. JNCI Journal of the National Cancer Institute 103:1, 16-20
CrossRef101
W. Zhang, T. Winder, Y. Ning, A. Pohl, D. Yang, M. Kahn, G. Lurje, M. J. LaBonte, P. M. Wilson, M. A. Gordon, S. Hu-Lieskovan, D. J. Mauro, C. Langer, E. K. Rowinsky, H.- J. Lenz. (2011) A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Annals of Oncology 22:1, 104-109
CrossRef102
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Nitin N. Sriramanakoppa, Vivian M. Mendonca, Sangameshwar B. Mahagaonkar. (2011) Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. International Journal of Technology Assessment in Health Care 27:01, 23-30
CrossRef103
Penelope Bradbury, John Hilton, Lesley Seymour. (2011) Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clinical Investigation 1:1, 33-44
CrossRef104
T. R. Asmis, E. Powell, C. S. Karapetis, D. J. Jonker, D. Tu, M. Jeffery, N. Pavlakis, P. Gibbs, L. Zhu, D.- A. Dueck, R. Whittom, C. Langer, C. J. O'Callaghan. (2011) Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology 22:1, 118-126
CrossRef105
D.P. Modest, A. Jung, N. Moosmann, R.P. Laubender, C. Giessen, C. Schulz, M. Haas, J. Neumann, S. Boeck, T. Kirchner, V. Heinemann, S. Stintzing. (2011) The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. International Journal of Cancern/a-n/a
CrossRef106
Peter A. Gerber, Gabriela Kukova, Bettina A. Buhren, Bernhard Homey. (2011) Density of <i>Demodex folliculorum</i> in Patients Receiving Epidermal Growth Factor Receptor Inhibitors. Dermatology 222:2, 144-147
CrossRef107
Janine M Davies, Dimitri Trembath, Allison M Deal, William K Funkhouser, Benjamin F Calvo, Timothy Finnegan, Karen E Weck, Joel E Tepper, Bert H O'Neil. (2011) Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiation Oncology 6:1, 114
CrossRef108
Xiaoqun Sun, Paul Peng, Dongsheng Tu. (2011) Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion. Contemporary Clinical Trials 32:1, 108-113
CrossRef109
Kevin M. Sullivan, Peter S. Kozuch. (2011) Impact of KRAS Mutations on Management of Colorectal Carcinoma. Pathology Research International 2011, 1-11
CrossRef110
Mariusz P. Madej, Gregory Coia, Charlotte C. Williams, Joanne M. Caine, Lesley A. Pearce, Rebecca Attwood, Nick A. Bartone, Olan Dolezal, Rebecca M. Nisbet, Stewart D. Nuttall, Timothy E. Adams. (2011) Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation. Biotechnology and Bioengineeringn/a-n/a
CrossRef111
Ulrich Gatzemeier, Joachim von Pawel, Ihor Vynnychenko, Petr Zatloukal, Filippo de Marinis, Wilfried EE Eberhardt, Luis Paz-Ares, Karl-Maria Schumacher, Thomas Goddemeier, Kenneth J O'Byrne, Robert Pirker. (2011) First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. The Lancet Oncology 12:1, 30-37
CrossRef112
N. Ogasawara, H. Bando, Y. Kawamoto, T. Yoshino, K. Tsuchihara, A. Ohtsu, H. Esumi. (2011) Feasibility and Robustness of Amplification Refractory Mutation System (ARMS)-based KRAS Testing Using Clinically Available Formalin-fixed, Paraffin-embedded Samples of Colorectal Cancers. Japanese Journal of Clinical Oncology 41:1, 52-56
CrossRef113
J. Sastre, E. Aranda, C. Grávalos, B. Massutí, M. Varella-Garcia, F. Rivera, G. Soler, A. Carrato, J.L. Manzano, E. Díaz-Rubio, M. Hidalgo. (2011) First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Critical Reviews in Oncology/Hematology 77:1, 78-84
CrossRef114
Xue Song, Zhongyun Zhao, Beth Barber, Christopher Gregory, Peter Feng Wang, Stacey R. Long. (2011) Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Current Medical Research and Opinion 27:1, 123-130
CrossRef115
E. Parmelli, D. Papini, L. Moja, E. Bandieri, M. Belfiglio, G. Ciccone, R. De Palma, M. Leoni, G. Longo, N. Magrini, I. Moschetti, A. Liberati. (2011) Updating clinical recommendations for breast, colorectal and lung cancer treatments: an opportunity to improve methodology and clinical relevance. Annals of Oncology 22:1, 188-194
CrossRef116
Efsevia Vakiani, David B Solit. (2011) KRAS and BRAF: drug targets and predictive biomarkers. The Journal of Pathology 223:2, 220-230
CrossRef117
Robert Königsberg, Wolfgang Hulla, Martin Klimpfinger, Angelika Reiner-Concin, Tanja Steininger, Wilfried Büchler, Robert Terkola, Christian Dittrich. (2011) Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients. Oncology 81:5-6, 359-364
CrossRef118
Kohei Shitara, Satoshi Yuki, Motoki Yoshida, Daisuke Takahari, Setsuo Utsunomiya, Tomoya Yokota, Yozo Sato, Yoshitaka Inaba, Masahiro Tajika, Hiroki Kawai, Hidekazu Yamaura, Mina Kato, Kentaro Yamazaki, Yoshito Komatsu, Kei Muro. (2010) Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Investigational New Drugs
CrossRef119
Harold J. Wanebo, David Berz. (2010) The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors. Journal of Surgical Oncology 102:8, 891-897
CrossRef120
F Di Fiore, R Sesboüé, P Michel, J C Sabourin, T Frebourg. (2010) Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. British Journal of Cancer 103:12, 1765-1772
CrossRef121
Uzma Asghar, Eliza Hawkes, David Cunningham. (2010) Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 9:5, 274-281
CrossRef122
Eun Joo KANG, Yoon Ji CHOI, Jung Seon KIM, Seung Tae KIM, Kyong Hwa PARK, In Keun CHOI, Sang Chul OH, Jae Hong SEO, Sang Won SHIN, Jun Suk KIM, Yeul Hong KIM. (2010) Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. Asia-Pacific Journal of Clinical Oncology 6:4, 286-291
CrossRef123
Jiezhong Chen, Xu-Feng Huang, Andrew Katsifis. (2010) Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. Journal of Cellular Biochemistry 111:5, 1082-1086
CrossRef124
Hideyuki Nishiofuku, Toshihiro Tanaka, Takeshi Aramaki, Narikazu Boku, Yoshitaka Inaba, Yozo Sato, Masaki Matsuoka, Toshio Otsuji, Yasuaki Arai, Kimihiko Kichikawa. (2010) Hepatic Arterial Infusion of 5-Fluorouracil for Patients With Liver Metastases From Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter, Retrospective Analysis. Clinical Colorectal Cancer 9:5, 305-310
CrossRef125
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Wayne Cottrell, Biljana Spirovski, Jonathan Edwards. (2010) The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. Journal of Evaluation in Clinical Practiceno-no
CrossRef126
Ewa Anna Kosakowska, Rafał Stec, Radosław Charkiewicz, Marta Skoczek, Lech Chyczewski. (2010) Molecular differences in the <i>KRAS</i> gene mutation between a primary tumor and related metastatic sites - case report and a literature review. Folia Histochemica et Cytobiologica 48:4, 597-602
CrossRef127
Gopa Iyer, Matthew I Milowsky, Dean F Bajorin. (2010) Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Review of Anticancer Therapy 10:12, 1917-1932
CrossRef128
Raja Atreya, Maximilian J. Waldner, Markus F. Neurath. (2010) Molecular Imaging: Interaction Between Basic and Clinical Science. Gastroenterology Clinics of North America 39:4, 911-922
CrossRef129
Muhammad Wasif Saif, Kristin Kaley, Edward Chu, M. Sitki Copur. (2010) Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions. Clinical Colorectal Cancer 9:5, 315-318
CrossRef130
William Pao, Juliann Chmielecki. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer 10:11, 760-774
CrossRef131
Rocío García-Carbonero, M. Auxiliadora Gómez España, Enrique Casado Sáenz, Vicente Alonso Orduña, Andrés Cervantes Ruipérez, Javier Gallego Plazas, Pilar García Alfonso, Ignacio Juez Martel, Encarnación González Flores, María Lomas Garrido, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clinical and Translational Oncology 12:11, 729-734
CrossRef132
Michele Visentin, Paola Biason, Giuseppe Toffoli. (2010) Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. Pharmacology & Therapeutics 128:1, 82-90
CrossRef133
C.- H. Kohne. (2010) How to integrate molecular targeted agents in the continuum of care. Annals of Oncology 21:Supplement 7, vii134-vii139
CrossRef134
Lori M. Minasian, William R. Carpenter, Bryan J. Weiner, Darrell E. Anderson, Worta McCaskill-Stevens, Stefanie Nelson, Cynthia Whitman, Joseph Kelaghan, Ann M. O'Mara, Arnold D. Kaluzny. (2010) Translating research into evidence-based practice. Cancer 116:19, 4440-4449
CrossRef135
James E. Frampton. (2010) Cetuximab. Drugs 70:15, 1987-2010
CrossRef136
Greg Dueck, Neil Chua, Angeli Prasad, Daygen Finch, Doug Stewart, Darrell White, Richard van der Jagt, James Johnston, Andrew Belch, Tony Reiman. (2010) Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116:19, 4541-4548
CrossRef137
Armando Santoro, Lorenza Rimassa, Alberto F. Sobrero, Giovanni Citterio, Francesco Sclafani, Carlo Carnaghi, Anna Pessino, Francesco Caprioni, Valeria Andretta, Maria Chiara Tronconi, Giovanna Finocchiaro, Gloria Rossoni, Angela Zanoni, Chiara Miggiano, Gian-Paolo Rizzardi, Catia Traversari, Federico Caligaris-Cappio, Antonio Lambiase, Claudio Bordignon. (2010) Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. European Journal of Cancer 46:15, 2746-2752
CrossRef138
John C. Hall. (2010) How to dissect surgical journals: IV - Original articles. ANZ Journal of Surgery 80:10, 750-753
CrossRef139
Ajay Bansal, Xiaoying Liu, Douglas H. McGregor, Vikas Singh, Sandy Hall. (2010) Correlation of Epidermal Growth Factor Receptor With Morphological Features of Colorectal Advanced Adenomas: A Pilot Correlative Case Series. The American Journal of the Medical Sciences 340:4, 296-300
CrossRef140
Deric L. Wheeler, Emily F. Dunn, Paul M. Harari. (2010) Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology 7:9, 493-507
CrossRef141
Geraldine Perkins, Astrid Lièvre, Carole Ramacci, Tchao Méatchi, Aurélien de Reynies, Jean-François Emile, Valérie Boige, Gorana Tomasic, Jean-Baptiste Bachet, Fréderic Bibeau, Olivier Bouché, Frédérique Penault-Llorca, Jean-Louis Merlin, Pierre Laurent-Puig. (2010) Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. International Journal of Cancer 127:6, 1321-1331
CrossRef142
Sebastian L. Ochenduszko, Krzysztof Krzemieniecki. (2010) Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs 21:8, 737-748
CrossRef143
J. Ciccolini. (2010) Le panitumumab (Vectibix®) en oncologie digestive: quel rationnel pharmacologique et pharmacocinétique ?. Oncologie 12:9, 565-571
CrossRef144
Cheng E. Chee, Frank A. Sinicrope. (2010) Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterology Clinics of North America 39:3, 601-613
CrossRef145
S. Yousuf Zafar, David C. Currow, Christopher K. Daugherty, Amy P. Abernethy. (2010) Standards for Palliative Care Delivery in Oncology Settings. The Cancer Journal 16:5, 436-443
CrossRef146
Jan Ouwerkerk, Christine Boers-Doets. (2010) Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. European Journal of Oncology Nursing 14:4, 337-349
CrossRef147
David Paez, Laia Paré, Iñigo Espinosa, Juliana Salazar, Elisabeth Del Rio, Agustí Barnadas, Eugenio Marcuello, Montserrat Baiget. (2010) Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?. Cancer Science 101:9, 2048-2053
CrossRef148
Wangjun Liao, Yulin Liao, Jeff X. Zhou, Jianming Xie, Jinzhang Chen, Weizhen Huang, Rongcheng Luo. (2010) Gene Mutations in Epidermal Growth Factor Receptor Signaling Network and Their Association With Survival in Chinese Patients With Metastatic Colorectal Cancers. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 293:9, 1506-1511
CrossRef149
Raymond C. Wadlow, David P. Ryan. (2010) The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 116:15, 3537-3548
CrossRef150
Camilla Qvortrup, Benny Vittrup Jensen, Trine Lembrecht Jorgensen, Dorte Nielsen, Jon Kroll Bjerregaard, Per Pfeiffer. (2010) Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncologica 49:6, 833-836
CrossRef151
R. Adam, D. G. Haller, G. Poston, J.- L. Raoul, J.- P. Spano, J. Tabernero, E. Van Cutsem. (2010) Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Annals of Oncology 21:8, 1579-1584
CrossRef152
Edouard J. Trabulsi, Jean Hoffman-Censits. (2010) Chemotherapy for Penile and Urethral Carcinoma. Urologic Clinics of North America 37:3, 467-474
CrossRef153
Arsénio M. Fialho, Ananda M. Chakrabarty. 2010. Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design. , 179-198.
CrossRef154
Jolien Tol, Jeroen R. Dijkstra, Marjolein Klomp, Steven Teerenstra, Martin Dommerholt, M. Elisa Vink-Börger, Patricia H. van Cleef, J. Han van Krieken, Cornelis J.A. Punt, Iris D. Nagtegaal. (2010) Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. European Journal of Cancer 46:11, 1997-2009
CrossRef155
Pasquale Comella, Rossana Casaretti, Antonio Avallone, Luca Franco. (2010) Optimizing the management of metastatic colorectal cancer. Critical Reviews in Oncology/Hematology 75:1, 15-26
CrossRef156
Stacey Stein, Deirdre J. Cohen, Howard S. Hochster. (2010) Treatment Paradigms With Epidermal Growth Factor Receptor–Targeted Therapies in Colorectal Cancer. Clinical Colorectal Cancer 9:0, S44-S50
CrossRef157
Jan Pander, Hans Gelderblom, Ninja F. Antonini, Jolien Tol, Johan H.J.M. van Krieken, Tahar van der Straaten, Cornelis J.A. Punt, Henk-Jan Guchelaar. (2010) Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European Journal of Cancer 46:10, 1829-1834
CrossRef158
Susana Banerjee, David Cunningham. (2010) Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions. Clinical Colorectal Cancer 9:0, S28-S35
CrossRef159
K. Shitara, T. Yokota, D. Takahari, T. Shibata, T. Ura, Y. Komatsu, S. Yuki, M. Yoshida, H. Takiuchi, S. Utsunomiya, Y. Yatabe, K. Muro. (2010) Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS. Japanese Journal of Clinical Oncology 40:7, 699-701
CrossRef160
J. Tabernero, F. Ciardiello, F. Rivera, E. Rodriguez-Braun, F. J. Ramos, E. Martinelli, M. E. Vega-Villegas, S. Rosello, S. Liebscher, O. Kisker, T. Macarulla, J. Baselga, A. Cervantes. (2010) Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Annals of Oncology 21:7, 1537-1545
CrossRef161
G. Folprecht. (2010) Aktuelle medikamentöse Therapie des metastasierten Kolonkarzinoms. Der Chirurg 81:6, 507-515
CrossRef162
Ezzeldin M. Ibrahim, Jamal M. Zekri, Bakr M. Bin Sadiq. (2010) Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. International Journal of Colorectal Disease 25:6, 713-721
CrossRef163
David S. Ettinger. (2010) Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 68:3, 332-337
CrossRef164
Anwar Tawfik Amin, Norio Shiraishi, Shigeo Ninomiya, Masaaki Tajima, Masafumi Inomata, Seigo Kitano. (2010) Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a murine model. Surgical Endoscopy 24:6, 1427-1433
CrossRef165
Javier Rodríguez, Antonio Viúdez, Mariano Ponz-Sarvisé, Isabel Gil-Aldea, Ana Chopitea, Jesús García-Foncillas, Ignacio Gil-Bazo. (2010) Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. Critical Reviews in Oncology/Hematology 74:3, 193-202
CrossRef166
Derek G. Power, Manish A. Shah, Timothy R . Asmis, Joaquin J . Garcia, Nancy E. Kemeny. (2010) Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Investigational New Drugs 28:3, 353-360
CrossRef167
Alejandro Forner, Carlos Rodríguez De Lope, María Reig, Jordi Bruix. (2010) Tratamiento del carcinoma hepatocelular avanzado. Gastroenterología y Hepatología 33:6, 461-468
CrossRef168
A Lièvre, H Blons, P Laurent-Puig. (2010) Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29:21, 3033-3043
CrossRef169
Joleen M. Hubbard, Steven R. Alberts. (2010) Treatment of Liver-Limited Metastatic Colorectal Cancer. The Cancer Journal 16:3, 235-240
CrossRef170
Gillian M. Keating. (2010) Panitumumab. Drugs 70:8, 1059-1078
CrossRef171
L. Liu, Y. Cao, A. Tan, C. Liao, Z. Mo, F. Gao. (2010) Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials. Colorectal Disease 12:5, 399-406
CrossRef172
César Serrano, Ben Markman, Josep Tabernero. (2010) Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy. The Cancer Journal 16:3, 226-234
CrossRef173
E. Van Cutsem, B. Nordlinger, A. Cervantes, . (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Annals of Oncology 21:Supplement 5, v93-v97
CrossRef174
Antoine Italiano, Isabelle Hostein, Isabelle Soubeyran, Thibault Fabas, Daniel Benchimol, Serge Evrard, Jean Gugenheim, Yves Becouarn, René Brunet, Marianne Fonck, Eric François, Marie-Christine Saint-Paul, Florence Pedeutour. (2010) KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications. Annals of Surgical Oncology 17:5, 1429-1434
CrossRef175
Ahmad D. Siddiqui, Bilal Piperdi. (2010) KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy. Annals of Surgical Oncology 17:4, 1168-1176
CrossRef176
Cristina Gravalos, Javier Cassinello, Pilar García-Alfonso, Antonio Jimeno. (2010) Integration of panitumumab into the treatment of colorectal cancer. Critical Reviews in Oncology/Hematology 74:1, 16-26
CrossRef177
Ben Markman, Víctor Rodríguez-Freixinos, Josep Tabernero. (2010) Biomarkers in colorectal cancer. Clinical and Translational Oncology 12:4, 261-270
CrossRef178
Daniel Renouf, Malcolm Moore. (2010) Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy 10:4, 529-540
CrossRef179
Lidan Liu, Yunfei Cao, Aihua Tan, Cun Liao, Feng Gao. (2010) Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemotherapy and Pharmacology 65:5, 849-861
CrossRef180
Salvatore Siena, Robert Glynne-Jones, Antoine Adenis, Josef Thaler, Peter Preusser, Enrique Aranda Aguilar, Matti S. Aapro, Anja H. Loos, Regina Esser, Hansjochen Wilke. (2010) Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 116:7, 1827-1837
CrossRef181
David Palma. (2010) Epidermal growth factor receptor (EGFR)-inhibitors, rashes, and survival: Is doxycycline the missing link?. Oral Oncology 46:4, e25-e26
CrossRef182
Ralph V. Boccia, Thomas M. Cosgriff, David L. Headley, Suprith Badarinath, Shaker R. Dakhil. (2010) A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer 9:2, 102-107
CrossRef183
Heather-Jane Au, Jolie Ringash, Michael Brundage, Michael Palmer, Harriet Richardson, Ralph M Meyer. (2010) Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Review of Pharmacoeconomics & Outcomes Research 10:2, 119-128
CrossRef184
Jonathan M. Street, James W. Dear. (2010) The application of mass-spectrometry-based protein biomarker discovery to theragnostics. British Journal of Clinical Pharmacology 69:4, 367-378
CrossRef185
Tim J. Kruser, Deric L. Wheeler. (2010) Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research 316:7, 1083-1100
CrossRef186
Carla Kurkjian, Shivaani Kummar. (2010) Advances in the Treatment of Metastatic Colorectal Cancer. Disease-a-Month 56:4, 187-203
CrossRef187
C Montagut, M Iglesias, M Arumi, B Bellosillo, M Gallen, A Martinez-Fernandez, L Martinez-Aviles, I Cañadas, A Dalmases, E Moragon, L Lema, S Serrano, A Rovira, F Rojo, J Bellmunt, J Albanell. (2010) Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. British Journal of Cancer 102:7, 1137-1144
CrossRef188
M. Cardo-Vila, R. J. Giordano, R. L. Sidman, L. F. Bronk, Z. Fan, J. Mendelsohn, W. Arap, R. Pasqualini. (2010) From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway. Proceedings of the National Academy of Sciences 107:11, 5118-5123
CrossRef189
Brigette BY Ma, Herbert Loong. (2010) Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Personalized Medicine 7:2, 121-124
CrossRef190
M. HEBBAR, P. FOURNIER, O. ROMANO. (2010) KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?. European Journal of Cancer Care 19:2, 167-171
CrossRef191
Hassane Izzedine, Rastilav Bahleda, David Khayat, Christophe Massard, Nicolas Magné, Jean Philippe Spano, Jean Charles Soria. (2010) Electrolyte disorders related to EGFR-targeting drugs. Critical Reviews in Oncology/Hematology 73:3, 213-219
CrossRef192
David Cunningham, Wendy Atkin, Heinz-Josef Lenz, Henry T Lynch, Bruce Minsky, Bernard Nordlinger, Naureen Starling. (2010) Colorectal cancer. The Lancet 375:9719, 1030-1047
CrossRef193
K. Shitara, D. Takahari, T. Yokota, T. Shibata, T. Ura, K. Muro, Y. Inaba, H. Yamaura, Y. Sato, M. Najima, S. Utsunomiya. (2010) Case Series of Cetuximab Monotherapy for Patients with Pre-treated Colorectal Cancer Complicated with Hyperbilirubinemia due to Severe Liver Metastasis. Japanese Journal of Clinical Oncology 40:3, 275-277
CrossRef194
N. Boku. (2010) Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan. Japanese Journal of Clinical Oncology 40:3, 183-187
CrossRef195
Jolien Tol, Cornelis J.A. Punt. (2010) Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clinical Therapeutics 32:3, 437-453
CrossRef196
Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Sook Ryun Park, Keun-Wook Lee, Hong Suk Song, Nam-Su Lee, Kyung Hee Lee, In Sil Choi, Moon Hee Lee, Min A Kim, Woo Ho Kim, Yung-Jue Bang, Tae-You Kim. (2010) Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Science 101:3, 793-799
CrossRef197
N C Tebbutt, M M Cummins, T Sourjina, A Strickland, G Van Hazel, V Ganju, D Gibbs, M Stockler, V Gebski, J Zalcberg. (2010) Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer 102:3, 475-481
CrossRef198
Frédéric Hollande, Julie Pannequin, Dominique Joubert. (2010) The long road to colorectal cancer therapy: Searching for the right signals. Drug Resistance Updates 13:1-2, 44-56
CrossRef199
Olivier Bouché, Giordano Domenico Beretta, Pilar García Alfonso, Michael Geissler. (2010) The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treatment Reviews 36, S1-S10
CrossRef200
Marco A. Pierotti, Tiziana Negri, Elena Tamborini, Federica Perrone, Sabrina Pricl, Silvana Pilotti. (2010) Targeted Therapies: The Rare Cancer Paradigm. Molecular Oncology 4:1, 19-37
CrossRef201
Zachary A. Knight, Henry Lin, Kevan M. Shokat. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10:2, 130-137
CrossRef202
Martin Goetz, Alex Ziebart, Sebastian Foersch, Michael Vieth, Maximilian J. Waldner, Peter Delaney, Peter R. Galle, Markus F. Neurath, Ralf Kiesslich. (2010) In Vivo Molecular Imaging of Colorectal Cancer With Confocal Endomicroscopy by Targeting Epidermal Growth Factor Receptor. Gastroenterology 138:2, 435-446
CrossRef203
D J Watkins, I Chau, D Cunningham, S S Mudan, N Karanjia, G Brown, S Ashley, A R Norman, A Gillbanks. (2010) Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. British Journal of Cancer 102:2, 255-261
CrossRef204
James A Bonner, Paul M Harari, Jordi Giralt, Roger B Cohen, Christopher U Jones, Ranjan K Sur, David Raben, Jose Baselga, Sharon A Spencer, Junming Zhu, Hagop Youssoufian, Eric K Rowinsky, K Kian Ang. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 11:1, 21-28
CrossRef205
Timothy J. Price, Niall C. Tebbutt, Christos S. Karapetis, Eva Segelov, Nick Pavlakis, David Cunningham, Alberto F. Sobrero, Daniel G. Haller, Jeremy D. Shapiro. (2010) Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer 9:1, 8-14
CrossRef206
Shishir K. Maithel, Michael I. D'Angelica. (2010) An Update on Randomized Clinical Trials in Advanced and Metastatic Colorectal Carcinoma. Surgical Oncology Clinics of North America 19:1, 163-181
CrossRef207
Marwan M. Fakih. (2010) <i>KRAS</i> Mutation Screening in Colorectal Cancer: From Paper to Practice. Clinical Colorectal Cancer 9:1, 22-30
CrossRef208
E. D. Saad, A. Katz, P. M. Hoff, M. Buyse. (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Annals of Oncology 21:1, 7-12
CrossRef209
P. Thermann, T. Seufferlein. (2010) Aktuelle Therapie des Kolonkarzinoms. Der Gastroenterologe 5:1, 57-71
CrossRef210
R. Sikorski, B. Yao. (2009) Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution. Science Translational Medicine 1:10, 10ps11-10ps11
CrossRef211
Peter R. Holt, Peter Kozuch, Seetal Mewar. (2009) Colon cancer and the elderly: From screening to treatment in management of GI disease in the elderly. Best Practice & Research Clinical Gastroenterology 23:6, 889-907
CrossRef212
G. Folprecht, C. Bokemeyer, J. Weitz. (2009) Therapie des metastasierten Kolonkarzinoms. Der Onkologe 15:12, 1223-1234
CrossRef213
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef214
W. H. Fiske, J. Tanksley, K. T. Nam, J. R. Goldenring, R. J. C. Slebos, D. C. Liebler, A. M. Abtahi, B. La Fleur, G. D. Ayers, C. D. Lind, M. K. Washington, R. J. Coffey. (2009) Efficacy of Cetuximab in the Treatment of Menetrier's Disease. Science Translational Medicine 1:8, 8ra18-8ra18
CrossRef215
F. Fiore, A. Oden-Gangloff, P. Michel. (2009) Cancer colorectal métastatique et thérapies ciblées. Côlon & Rectum 3:4, 230-238
CrossRef216
Jose A. García-Sáenz, Javier Sastre, Eduardo Díaz-Rubio García. (2009) Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. Clinical and Translational Oncology 11:11, 737-747
CrossRef217
Ben Markman, Jaume Capdevila, Elena Elez, Josep Tabernero. (2009) New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy 1:6, 965-982
CrossRef218
U. Settmacher, D. Bottke, A. Hochhaus, A. Stallmach. (2009) Interdisziplinarität am Beispiel gastrointestinaler Tumoren. Der Onkologe 15:11, 1110-1119
CrossRef219
Fang NIE, Jun SHEN, Jin Lu TONG, Xi Tao XU, Ming Ming ZHU, Zhi Hua RAN. (2009) Meta-analysis: The efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer. Journal of Digestive Diseases 10:4, 247-257
CrossRef220
Roy D Baynes, Jennifer Gansert. (2009) KRAS Mutational Status as a Predictor of Epidermal Growth Factor Receptor Inhibitor Efficacy in Colorectal Cancer. American Journal of Therapeutics 16:6, 554-561
CrossRef221
C Pinto, F Di Fabio, C Barone, S Siena, A Falcone, S Cascinu, F L Rojas Llimpe, G Stella, G Schinzari, S Artale, V Mutri, S Giaquinta, L Giannetta, A Bardelli, A A Martoni. (2009) Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cancer 101:8, 1261-1268
CrossRef222
S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, A. Bardelli. (2009) Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. JNCI Journal of the National Cancer Institute 101:19, 1308-1324
CrossRef223
E. Martinelli, R. De Palma, M. Orditura, F. De Vita, F. Ciardiello. (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clinical & Experimental Immunology 158:1, 1-9
CrossRef224
Lucia Regales, Yixuan Gong, Ronglai Shen, Elisa de Stanchina, Igor Vivanco, Aviva Goel, Jason A. Koutcher, Maria Spassova, Ouathek Ouerfelli, Ingo K. Mellinghoff, Maureen F. Zakowski, Katerina A. Politi, William Pao. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Journal of Clinical Investigation
CrossRef225
N. Mittmann, H.-J. Au, D. Tu, C. J. O'Callaghan, P. K. Isogai, C. S. Karapetis, J. R. Zalcberg, W. K. Evans, M. J. Moore, J. Siddiqui, B. Findlay, B. Colwell, J. Simes, P. Gibbs, M. Links, N. C. Tebbutt, D. J. Jonker, . (2009) Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. JNCI Journal of the National Cancer Institute 101:17, 1182-1192
CrossRef226
A. Osio, C. Mateus, J.-C. Soria, C. Massard, D. Malka, V. Boige, B. Besse, C. Robert. (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. British Journal of Dermatology 161:3, 515-521
CrossRef227
B. Venugopal, J. Cassidy. (2009) How to integrate biologicals in the continuum of care. European Journal of Cancer 45, 57-69
CrossRef228
Liangping Xia, Guifang Guo, Huijuan Qiu, Bei Zhang, Feifei Zhou. (2009) Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. The Chinese-German Journal of Clinical Oncology 8:9, 526-530
CrossRef229
Mauro Moroni, Giovanna Marrapese, Silvio Veronese. (2009) EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy. Oncology Reviews 3:3, 187-193
CrossRef230
Carla Kurkjian, Shivaani Kummar. (2009) Advances in the Treatment of Metastatic Colorectal Cancer. American Journal of Therapeutics 16:5, 412-420
CrossRef231
Siegfried Segaert, Gabriela Chiritescu, Liesbeth Lemmens, Kristien Dumon, Eric Van Cutsem, Sabine Tejpar. (2009) Skin toxicities of targeted therapies. European Journal of Cancer 45, 295-308
CrossRef232
Alison K. Ramsay, Hing Y. Leung. (2009) Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science 117:6, 209-228
CrossRef233
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, G Masi, I Stasi, E Canestrari, E Rulli, I Floriani, K Bencardino, N Galluccio, V Catalano, G Tonini, M Magnani, G Fontanini, F Basolo, A Falcone, F Graziano. (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer 101:4, 715-721
CrossRef234
T. Fojo, C. Grady. (2009) How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 101:15, 1044-1048
CrossRef235
GL Ray, KE Baidoo, KJ Wong, M Williams, K Garmestani, MW Brechbiel, DE Milenic. (2009) Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. British Journal of Pharmacology 157:8, 1541-1548
CrossRef236
Johnny Kao, Stuart Packer, Ha Linh Vu, Myron E. Schwartz, Max W. Sung, Richard G. Stock, Yeh-Chi Lo, Delphine Huang, Shu-Hsia Chen, Jamie A. Cesaretti. (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer 115:15, 3571-3580
CrossRef237
Russell J. Schilder, Michael W. Sill, Yi-Chun Lee, Robert Mannel. (2009) A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix. International Journal of Gynecological Cancer 19:5, 929-933
CrossRef238
H. Richard Alexander, David L. Bartlett, Steven K. Libutti, James F. Pingpank, Douglas L. Fraker, Richard Royal, Seth M. Steinberg, Cynthia B. Helsabeck, Tatiana H. Beresneva. (2009) Analysis of Factors Associated with Outcome in Patients Undergoing Isolated Hepatic Perfusion for Unresectable Liver Metastases from Colorectal Center. Annals of Surgical Oncology 16:7, 1852-1859
CrossRef239
Helen X. Chen, Jessica N. Cleck, Rochelle Coelho, Janet E. Dancey. (2009) Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer 33:4, 245-294
CrossRef240
U. Wedding. (2009) Schmerztherapie bei onkologischen Patienten. Der Onkologe 15:7, 663-668
CrossRef241
I Chau, D Cunningham. (2009) Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer 100:11, 1704-1719
CrossRef242
Astrid Lièvre, Pierre Laurent-Puig. (2009) Genetics: Predictive value of KRAS mutations in chemoresistant CRC. Nature Reviews Clinical Oncology 6:6, 306-307
CrossRef243
George J. Chang. (2009) INVITED COMMENTARY. Diseases of the Colon & Rectum 52:6, 1152-1153
CrossRef244
Emmanuel Mitry, Astrid Lièvre, Jean-Baptiste Bachet, Philippe Rougier. (2009) Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. International Journal of Colorectal Disease 24:6, 605-612
CrossRef245
(2009) Chemotherapy and Immunotherapy in Metastatic Colorectal Cancer. New England Journal of Medicine 360:20, 2134-2136
Full Text246
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef247
BM Fine, L Amler. (2009) Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective. Clinical Pharmacology & Therapeutics 85:5, 535-538
CrossRef248
Robin K. Kelley, Alan P. Venook. (2009) Drug development in advanced colorectal cancer: Challenges and opportunities. Current Oncology Reports 11:3, 175-185
CrossRef249
Hiroyasu Yasuda, Katsutoshi Nakayama, Takahiko Sasaki, Kazuhiro Yanagihara. (2009) Research Highlights. Immunotherapy 1:3, 337-340
CrossRef250
Jose Perez-Garcia, Jaume Capdevila, Teresa Macarulla, Francisco Javier Ramos, Elena Elez, Manuel Ruiz-Echarri, Josep Tabernero. (2009) Advances in targeted therapies for metastatic colorectal cancer. Therapy 6:3, 321-333
CrossRef251
H. Yasui, T. Yoshino, N. Boku, Y. Onozawa, S. Hironaka, A. Fukutomi, K. Yamazaki, K. Taku, T. Kojima, N. Machida. (2009) Retrospective Analysis of S-1 Monotherapy in Patients with Metastatic Colorectal Cancer After Failure to Fluoropyrimidine and Irinotecan or to Fluoropyrimidine, Irinotecan and Oxaliplatin. Japanese Journal of Clinical Oncology 39:5, 315-320
CrossRef252
E. Van Cutsem, J. Oliveira, . (2009) Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv61-iv63
CrossRef253
Mitchell Kamrava, Olivier Rixe, James L Gulley. (2009) Research Highlights. Therapy 6:3, 305-308
CrossRef254
A Oden-Gangloff, F Di Fiore, F Bibeau, A Lamy, G Bougeard, F Charbonnier, F Blanchard, D Tougeron, M Ychou, F Boissière, F Le Pessot, J-C Sabourin, J-J Tuech, P Michel, T Frebourg. (2009) TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. British Journal of Cancer 100:8, 1330-1335
CrossRef255
Michael Dougan, Glenn Dranoff. (2009) Immune Therapy for Cancer. Annual Review of Immunology 27:1, 83-117
CrossRef256
Steven R. Alberts. (2009) Do we need biologic agents in preoperative systemic therapy of liver metastases?. Current Colorectal Cancer Reports 5:2, 114-119
CrossRef257
Cathy Eng. (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nature Reviews Clinical Oncology 6:4, 207-218
CrossRef258
Giuseppe Aprile, Elisa Zanon, Francesco Tuniz, Emiliana Iaiza, Federica Pauli, Nicoletta Pella, Stefano Pizzolitto, Alberto Buffoli, Andrea Piga, Miran Skrap, Gianpiero Fasola. (2009) Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. Journal of Cancer Research and Clinical Oncology 135:3, 451-457
CrossRef259
Byung Woog Kang, Tae Won Kim, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Chang Sik Yu, Jin Cheon Kim, Jong Hoon Kim, Yoon-Koo Kang, Jung Shin Lee. (2009) Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Medical Oncology 26:1, 32-37
CrossRef260
Astrid Lièvre, Pierre Laurent-Puig. (2009) Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. Personalized Medicine 6:2, 145-157
CrossRef261
Antonio Jimeno, Wells A. Messersmith, Fred R. Hirsch, Wilbur A. Franklin, S Gail Eckhardt. (2009) KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer. The Cancer Journal 15:2, 110-113
CrossRef262
Tol, Jolien, Koopman, Miriam, Cats, Annemieke, Rodenburg, Cees J., Creemers, Geert J.M., Schrama, Jolanda G., Erdkamp, Frans L.G., Vos, Allert H., van Groeningen, Cees J., Sinnige, Harm A.M., Richel, Dirk J., Voest, Emile E., Dijkstra, Jeroen R., Vink-Börger, Marianne E., Antonini, Ninja F., Mol, Linda, van Krieken, Johan H.J.M., Dalesio, Otilia, Punt, Cornelis J.A., . (2009) Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. New England Journal of Medicine 360:6, 563-572
Full Text263
Raquel Seruca, Sérgia Velho, Carla Oliveira, Marina Leite, Paulo Matos, Peter Jordan. (2009) Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. Expert Review of Gastroenterology & Hepatology 3:1, 5-9
CrossRef264
S-W Han, D-Y Oh, S-A Im, S R Park, K-W Lee, H S Song, N-S Lee, K H Lee, I S Choi, M H Lee, M A Kim, W H Kim, Y-J Bang, T-Y Kim. (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. British Journal of Cancer 100:2, 298-304
CrossRef265
Amir Harandi, Aisha S. Zaidi, Abigail M. Stocker, Damian A. Laber. (2009) Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology 2009, 1-14
CrossRef266
John L. Marshall. (2009) Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?. Journal of Oncology 2009, 1-9
CrossRef267
B. Mühlhaupt, R. Schöfl, T. Rösch, P. Bauerfeind, W. Schwizer, H.-P. Wirth, G. Rogler, M. Fried. (2009) Gastro-Highlights 2008. Der Gastroenterologe 4:1, 74-77
CrossRef268
F. Schmitz. (2009) KRAS-Genotyp kodiert für das Ansprechen einer Cetuximab-Therapie beim fortgeschrittenen kolorektalen Karzinom. Der Gastroenterologe 4:1, 52-54
CrossRef269
Herbert H. Loong, Brigette B. Ma, Anthony T. C. Chan. (2009) Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer. Journal of Oncology 2009, 1-6
CrossRef270
Han van Krieken, Jolien Tol. (2009) Setting future standards for KRAS testing in colorectal cancer. Pharmacogenomics 10:1, 1-3
CrossRef271
Alastair CJ Windsor, Richard Cohen, Long R Jiao, Justin Stebbing. (2008) Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear. Future Oncology 4:6, 741-744
CrossRef272
Jeffrey W. Clark. (2008) Therapy for Unresectable Metastatic Colorectal Cancer. Seminars in Colon and Rectal Surgery 19:4, 216-225
CrossRef273
David R Fogelman, Scott Kopetz, Cathy Eng. (2008) Emerging drugs for colorectal cancer. Expert Opinion on Emerging Drugs 13:4, 629-642
CrossRef274
Arun AZAD, Niall C TEBBUTT. (2008) Predicting the response to targeted therapy in metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology 4:4, 208-217
CrossRef275
Marwan Fakih. (2008) The Role of Targeted Therapy in the Treatment of Advanced Colorectal Cancer. Current Treatment Options in Oncology 9:4-6, 357-374
CrossRef276
Dina K Patel. (2008) Clinical Use of Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer. Pharmacotherapy 28:11 Part 2, 31S-41S
CrossRef277
Gregory J. Riely, Marc Ladanyi. (2008) KRAS Mutations. The Journal of Molecular Diagnostics 10:6, 493-495
CrossRef278
J. H. J. M. Krieken, A. Jung, T. Kirchner, F. Carneiro, R. Seruca, F. T. Bosman, P. Quirke, J. F. Fléjou, T. Plato Hansen, G. Hertogh, P. Jares, C. Langner, G. Hoefler, M. Ligtenberg, D. Tiniakos, S. Tejpar, G. Bevilacqua, A. Ensari. (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Archiv 453:5, 417-431
CrossRef279
Joaquin Garcia, Gregory J. Riely, Khedoudja Nafa, Marc Ladanyi. (2008) KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Seminars in Diagnostic Pathology 25:4, 288-294
CrossRef280
Karapetis, Christos S., Khambata-Ford, Shirin, Jonker, Derek J., O'Callaghan, Chris J., Tu, Dongsheng, Tebbutt, Niall C., Simes, R. John, Chalchal, Haji, Shapiro, Jeremy D., Robitaille, Sonia, Price, Timothy J., Shepherd, Lois, Au, Heather-Jane, Langer, Christiane, Moore, Malcolm J., Zalcberg, John R., . (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine 359:17, 1757-1765
Full Text281
Messersmith, Wells A., Ahnen, Dennis J., . (2008) Targeting EGFR in Colorectal Cancer. New England Journal of Medicine 359:17, 1834-1836
Full Text282
M. Yong, B. Tolner, S. Nagl, R.B. Pedley, K. Chester, A.J. Green, A. Mayer, S. Sharma, R. Begent. (2008) Data standards for minimum information collection for antibody therapy experiments. Protein Engineering Design and Selection 22:3, 221-224
CrossRef283
Eric Van Cutsem, Sabine Tejpar. (2008) Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era. Targeted Oncology 3:4, 223-225
CrossRef284
Diane E. Milenic, Karen J. Wong, Kwamena E. Baidoo, Geoffrey L. Ray, Kayhan Garmestani, Mark Williams, Martin W. Brechbiel. (2008) Cetuximab: Preclinical Evaluation of a Monoclonal Antibody Targeting EGFR for Radioimmunodiagnostic and Radioimmunotherapeutic Applications. Cancer Biotherapy & Radiopharmaceuticals 23:5, 619-632
CrossRef285
Shirin Khambata-Ford, Christopher T. Harbison, David J. Mauro. (2008) Predictive markers of cetuximab efficacy in metastatic colorectal cancer. Current Colorectal Cancer Reports 4:4, 184-192
CrossRef286
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef287
Josep M. Llovet, Jordi Bruix. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:4, 1312-1327
CrossRef288
M. Tahara, K. Shirao, N. Boku, K. Yamaguchi, Y. Komatsu, Y. Inaba, T. Arai, N. Mizunuma, T. Satoh, H. Takiuchi, T. Nishina, Y. Sakata. (2008) Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines. Japanese Journal of Clinical Oncology 38:11, 762-769
CrossRef289
David E. Gerber. (2008) EGFR inhibition in the treatment of non-small cell lung cancer. Drug Development Research 69:6, 359-372
CrossRef290
Marwan Fakih. (2008) Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?. Expert Review of Anticancer Therapy 8:9, 1471-1480
CrossRef291
P Martín-Martorell, S Roselló, E Rodríguez-Braun, I Chirivella, A Bosch, A Cervantes. (2008) Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. British Journal of Cancer 99:3, 455-458
CrossRef292
Sonia Garofalo, Roberta Rosa, Roberto Bianco, Giampaolo Tortora. (2008) EGFR-targeting agents in oncology. Expert Opinion on Therapeutic Patents 18:8, 889-901
CrossRef293
M. PEETERS, J. BALFOUR, D. ARNOLD. (2008) Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Alimentary Pharmacology & Therapeutics 28:3, 269-281
CrossRef294
F. Perrone, A. Lampis, M. Orsenigo, M. Di Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, L. Bertario, E. Leo, M. A. Pierotti, S. Pilotti. (2008) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Annals of Oncology 20:1, 84-90
CrossRef295
F Cappuzzo, M Varella-Garcia, G Finocchiaro, M Skokan, S Gajapathy, C Carnaghi, L Rimassa, E Rossi, C Ligorio, L Di Tommaso, A J Holmes, L Toschi, G Tallini, A Destro, M Roncalli, A Santoro, P A Jänne. (2008) Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. British Journal of Cancer 99:1, 83-89
CrossRef296
X.-M. Yang, J.-L. Xing, C.-G. Liao, X.-Y. Yao, Y. Li, Z.-N. Chen. (2008) High Efficiency Reconstitution of a Human–Mouse Chimeric Fab of CAb-1 Antibody Specific to Human Colon Cancer. Scandinavian Journal of Immunology 68:1, 12-21
CrossRef297
Klaus Strebhardt, Axel Ullrich. (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer 8:6, 473-480
CrossRef298
Jim Cassidy. (2008) Cetuximab for the treatment of patients with colorectal cancer. Nature Clinical Practice Oncology
CrossRef299
Teri N. Kreisl. (2008) Neurologic complications of antitumor antibody therapies. Current Neurology and Neuroscience Reports 8:3, 259-263
CrossRef300
Brian M. Wolpin, Robert J. Mayer. (2008) Systemic Treatment of Colorectal Cancer. Gastroenterology 134:5, 1296-1310.e1
CrossRef301
Rebecca A Herbertson, Chris Karapetis, Tim Price, Niall Tebbutt, Nick Pavlakis, Rebecca A Herbertson. 2008. Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. .
CrossRef302
Martin H Fenner, Gernot Beutel, Viktor Grünwald. (2008) Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs 17:4, 511-522
CrossRef303
Rachel Wong, David Cunningham. (2008) What is the impact of biologicals in colorectal cancer?. Targeted Oncology 3:2, 59-69
CrossRef304
Ciardiello, Fortunato, Tortora, Giampaolo, . (2008) EGFR Antagonists in Cancer Treatment. New England Journal of Medicine 358:11, 1160-1174
Full Text305
(2008) Cetuximab for Colorectal Cancer. New England Journal of Medicine 358:11, 1195-1197
Full Text306
Christopher Jackson, David Cunningham. (2008) Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. European Journal of Cancer 44:5, 652-662
CrossRef307
Nicolas Moosmann, Volker Heinemann. (2008) Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Review of Anticancer Therapy 8:3, 319-329
CrossRef308
(2008) Cetuximab improves survival in patients with colorectal cancer. Nature Clinical Practice Gastroenterology & Hepatology 5:3, 122-122
CrossRef309
J. P. Gerard, E. Francois, P. Follana. (2008) Commentary. Colorectal Disease 10:3, 218-221
CrossRef310
Elza Friedländer, Márk Barok, János Szöllősi, György Vereb. (2008) ErbB-directed immunotherapy: Antibodies in current practice and promising new agents. Immunology Letters 116:2, 126-140
CrossRef311
I Zlobec, T Vuong, C C Compton, A Lugli, R P Michel, S Hayashi, J R Jass. (2008) Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. British Journal of Cancer 98:2, 450-456
CrossRef312
Fotios Loupakis, Enrico Vasile, Daniele Santini, Gianluca Masi, Alfredo Falcone, Francesco Graziano. (2008) EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics 9:1, 55-69
CrossRef313
Jae Woo Park, Sun-Mi Moon, Dae-Yong Hwang. (2008) Retrospective Analysis of Patients Treated with Cetuximab plus FOLFIRI for Previous Irinotecan-combined Chemotherapy in Metastatic Colorectal Cancer. Journal of the Korean Society of Coloproctology 24:5, 345
CrossRef314
Javier Castro-Carpeño, Cristóbal Belda-Iniesta, Enrique Casado Sáenz, Elena Hernández Agudo, Jaime Feliu Batlle, Manuel González Barón. (2008) EGFR and colon cancer: a clinical view. Clinical and Translational Oncology 10:1, 6-13
CrossRef315
Eric Van Cutsem, Karen Geboes. (2007) The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Practice & Research Clinical Gastroenterology 21:6, 1089-1108
CrossRef316
Stephanie K A Blick, Lesley J Scott. (2007) Cetuximab. Drugs 67:17, 2585-2607
CrossRef
- Letters
